Andrew Yue, MD
Nephrology · Los Angeles, CANPI 1861792541
Payments from drug & device makers
Across 129 payments — averaging $21.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$559
- Amgen$426
- Otsuka America Pharmaceutical, Inc.$350
- Mallinckrodt Hospital Products Inc.$336
- Akebia Therapeutics Inc$335
- Calliditas Therapeutics US Inc.$118
- plus $667 from 11 others
What the payments were for
- Food & beverage$2,788100%
- Education$30%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 29 | $559 |
| Amgen(2 entities) | 17 | $426 |
| Otsuka America Pharmaceutical, Inc. | 17 | $350 |
| Mallinckrodt Hospital Products Inc. | 14 | $336 |
| Akebia Therapeutics Inc | 13 | $335 |
| Calliditas Therapeutics US Inc. | 6 | $118 |
| Ultragenyx Pharmaceutical Inc. | 6 | $109 |
| Vifor Pharma, Inc. | 5 | $107 |
| Fresenius USA Marketing, Inc. | 4 | $69 |
| GSK | 3 | $66 |
| OPKO Pharmaceuticals, LLC | 4 | $64 |
| Travere Therapeutics, Inc. | 2 | $56 |
| Mallinckrodt Enterprises LLC | 2 | $44 |
| Bayer | 2 | $43 |
| Novo Nordisk | 2 | $42 |
| Aurinia Pharma U.S., Inc. | 2 | $41 |
| Boehringer Ingelheim | 1 | $26 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vafseo$127
How this compares
$2,791 in reported general payments places this provider in the 60th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sodium Chloride0.9 % Sodium Chloride | 15 | $684 |
| Sevelamer Carbonate | 11 | $598 |
| Cinacalcet Hcl | 11 | $396 |
| Nifedipine ErNifedipine | 12 | $326 |
| Furosemide | 30 | $151 |
| Amlodipine Besylate | 15 | $103 |
| Allopurinol | 23 | $43 |
| Prednisone | 12 | $23 |
| Ciprofloxacin Hcl | 13 | $20 |
| Spironolactone | 11 | $6 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Los Angeles
- Anjay RastogiLos Angeles$6.3M
- Mohamed El-ShahawyLos Angeles$4.4M
- Suphamai BunnapradistLos Angeles$1.7M
- Victor CarabelloLos Angeles$1.4M
- John SimLos Angeles$1.3M
- Tariq ShahLos Angeles$1.2M
- Michael LevineLos Angeles$867K
- Aamir JamalSan Dimas$5.5M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.